Company / SG&A Expense
ENvue Medical, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$3.5M
FY2025
5-year range
$3.5M / $5.1M
FY2021-FY2025
Trend
-11.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has declined for 3 consecutive years, from $5M in FY2022 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -2.0%.
Improved from $4M to $3M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- -2.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENvue Medical, Inc.'s sg&a expense has declined for 3 consecutive years.
- 5-year CAGR of -2.0%, indicating a declining trend.
- In FY2025, sg&a expense decreased 11.8% year-over-year.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.5M | -11.8% |
| FY2024 | $3.9M | -0.2% |
| FY2023 | $3.9M | -22.3% |
| FY2022 | $5.1M | +34.2% |
| FY2021 | $3.8M | -1.4% |
| FY2020 | $3.8M | +44.9% |
| FY2019 | $2.6M | +26.5% |
| FY2018 | $2.1M | +53.3% |
| FY2017 | $1.4M | +82.2% |
| FY2016 | $746.0K | +26.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026